The RCVS Disciplinary Committee has reprimanded a veterinary surgeon for submitting a certificate of Clinical Inspection for Veterinary Inspectors ("TB52") for tuberculin tests he had undertaken on cattle, despite knowing that he had not fully complied with the standard operating procedures (SOP) for these tests.
At the outset of the three-day hearing, John Wilson admitted that, when acting as an Official Veterinarian (OV) he had not carried out tuberculin tests on cattle at a Wiltshire farm on 19 May 2011 strictly in accordance with the SOP required by the Animal Health and Veterinary Laboratories Agency (AHVLA), an executive agency of Defra.
The admitted shortcomings were that on 19 May, the second day of testing, Mr Wilson had failed to confirm the identity of all the animals, failed to inspect the animals digitally (ie using his hands) and had not measured the fold of skin at the injection site of all the animals. The College argued that this was contrary to the directions of the AHVLA and, in subsequently signing the TB52 certificate, he was either dishonest or should have known that the certification was incorrect. Mr Wilson admitted that he ought to have known the certification was incorrect but denied dishonesty, because he believed that he had conducted the test in a satisfactory manner and had correctly identified all the reactors in the herd.
Mr Wilson was a veterinary surgeon of over 40 years experience and unblemished record, and the Committee found his account of events to be accurate and honest. He said the farm involved was unprepared and test arrangements were chaotic, with poor handling facilities, and he would have been concerned for the safety of the animals and their handlers if he had complied fully with the SOP. He had advised the farmer to delay the test but his advice was rejected.
The Committee accepted that the testing had been carried out under exceptional and difficult circumstances. It noted that Mr Wilson had identified a reactor and taken appropriate actions, knowing that the outcome would be the quarantining of the whole herd. He had made no financial or other gain, other than the nominal fee charged for the work. Although failing to comply with the SOP fell short of what was expected of a veterinary surgeon, because of these circumstances, and as he had acted in what he considered to be the best interests of the animals and personnel, these actions did not amount to serious professional misconduct.
The Committee found that, even allowing for these difficulties and concerns, in signing the TB52 certificate a few days later, without any qualification, Mr Wilson ought to have known that it was incorrect, and his actions fell far short of the standards expected of the veterinary profession. They did not however find that he had been dishonest.
The Committee stressed the importance attached to accurate and reliable certification, in maintaining the confidence of the public and the profession, and in ensuring animal welfare.
Professor Lees, chairing and speaking on behalf of the committee said: "The Committee is aware, as confirmed by AHVLA, that this is a single, isolated event and the first offence in some 40 years of the Respondent working as a LVI [local veterinary inspector] or OV. After considering all the mitigating factors.and, given the exceptional circumstances of this specific case, the decision of the Committee is to reprimand Mr Wilson."
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
References
1. 1987 (Taranaki, North Island)
Life Technologies Animal Health has announced the launch of a new qPCR test to improve the diagnosis of mastitis and respiratory disease caused by Mycoplasma bovis.
According to the company, the TaqVet Mycoplasma Bovis (M. bovis) polymerase chain reaction (PCR) kit is based on a new target gene in the M. bovis genome and thus can distinguish better between infections caused by M. bovis and M. agalactiae - so there is less risk of false positive results and improved sensitivity and specificity.
The test is based on real-time PCR technology, and delivers results in two and a half hours.
Eric Sellal, Head of Animal Health EMEA at Life Technologies said: "The improved sensitivity of this new test means that veterinarians will be able to monitor dairy herds for sub-clinical infection using samples from the bulk tank. And of course it can also be used to diagnose mycoplasma infection in individual cases of clinical mastitis and respiratory disease."
Life Technologies says the test system incorporates a number of other improvements which simplify and speed up processing in the laboratory, including automatic extraction using magnetic bead technology.
It is estimated that bovine pneumonia costs the European industry around 500million Euros each year, with 30% accounted for by M. bovis. Other diseases associated with the organism include mastitis and arthritis.
Mycoplasma is slow and difficult to culture in the laboratory and current antibiotic treatment is not very cost-effective. Therefore, prevention is a cornerstone of M. bovis management.
The TaqVet Mycoplasma Bovis PCR kit will be made available in other EU countries and via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).
Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.
"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.
"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.
"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."
Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.
"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.
"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."
Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
Welsh Environment Minister, John Griffiths, has announced changes to some bovine TB cattle and surveillance controls to provide a higher level of protection against the disease.
The Minister confirmed that from 1 April 2013, some existing Pre Movement Testing exemptions will be amended. The main changes concern movements from markets and common land.
New key measures are:
The Minister announced that a new dedicated TB epidemiologist was to be appointed for Wales and that he or she would work within the AHVLA and focus on specific areas or clusters of disease. The postholder will be in place by April 2013.
He also announced new advice and support to farms dealing with breakdowns: "I have also asked officials to develop a way to provide additional advice and support to farmers to clear up breakdowns more quickly and efficiently. We have started to explore how private vets could become more involved with this new initiative called the Integrated Breakdown Management Project.
"I know that bovine TB is a devastating disease that has a big impact in rural communities. Since I launched the Strategic Framework for Bovine TB Eradication last March, we have kept the programme under constant review. With the new tools I have outlined today, we are addressing TB in livestock and wildlife and maintaining an effective eradication programme for the benefit of farmers, rural communities and the economy in general."
Elanco Animal Health is reminding vets about the importance of correctly interpreting oocyst counts in the diagnosis of coccidiosis during the post lambing period.
The company says scouring lambs that are failing to thrive should immediately ring the alarm bells for coccidiosis. Typically, oocyst counts of >20,000 per gram are cited as diagnostic for coccidiosis in sheep, but counts of up to 100,000 oocysts per gram have been reported in apparently healthy lambs and disease can also occur in the presence of low or negligible counts where there is gut damage but before oocysts have been shed.1 These discrepancies can lead to misdiagnosis and as such, oocyst counts should always be interpreted with care.
Oocysts of the fourteen Eimeria species described as specific to sheep are indistinguishable from each other by eye and only two species - E. ovinoidalis and E. crandallis, are actually pathogenic.1 For this reason, diagnosing coccidiosis based on clinical signs of diarrhoea and oocysts in their faeces alone can generate false positives. This could lead to important differentials, such as Nematodirus battus infection (for lambs at pasture) being left untreated.
According to the company, false negatives are also a concern, particularly as prompt treatment of clinical cases with an anti-coccidial, such as diclazuril (Vexocan® 2.5mg/ml oral suspension) has been proven to reduce the convalescence period.2 Shedding of oocysts varies with disease progression and faecal counts can fluctuate significantly.3 For example, a delay between the development of clinical signs and oocysts appearing in faeces is common. Another possibility is sub-clinical disease, with affected lambs showing no typical outward signs. The gut damage caused by the parasite can be significant in these animals though, adversely affecting growth rates.
Elanco says that for reliable diagnosis of coccidiosis, faecal oocyst counts should be considered alongside disease and farm history, followed with Eimeria species identification if possible. The disease typically affects groups of lambs aged between 3-8 weeks old and is often triggered by a stressor such as castration, weaning, turnout and/or bad weather. If clinical signs appear around three weeks after such an event, the suspicion of coccidiosis can be heightened. For some farms, predictable stressors cause disease outbreaks year after year and in these cases, a metaphylactic dose of Vecoxan® can be administered to susceptible lambs 14 days after the trigger event.
Finally, the company says veterinary surgeons should also not forget the importance of good management when advising farmers about coccidiosis control. Lambing pen and high traffic area hygiene and age batching lambs are essential for long term control.
Life Technologies has announced the launch of a new ELISA test for bluetongue virus (BTV) antibodies.
According to the company, studies have confirmed that the LSI VET Ruminant Bluetongue II-serum ELISA can detect antibodies to BTV in experimentally infected sheep after 6 days, and in cattle after 7-8 days - several days sooner than some other commercially available test kits, including the company's previous ELISA test which the new product has replaced.
Life Technologies asked the UK's Pirbright Institute, the European Union Reference Laboratory for BTV, to conduct a preliminary assessment of the new test. The new test was able to detect antibodies in all 24 BTV reference sera and BTV 26 held by Pirbright, and showed high sensitivity in a longitudinal study of experimentally infected animals.
The Pirbright study also demonstrated that the LSI VET Ruminant Bluetongue II-serum ELISA could detect BTV antibodies in cattle and sheep that had been vaccinated with an inactivated Bluetongue vaccine.
The new test was developed by Life Technologies Animal Health in its research laboratory near Lyon in France and will be available in EU countries via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
Norbrook Laboratories Ltd has launched the 2013 - 2014 edition of its UK Veterinary Surgeon's Product Compendium.
The compendium contains data sheets for the complete range of over 120 Norbrook products which are available in the UK and Northern Ireland, including 17 new products which have been launched since the last compendium was issued.
The compendium is available from your Norbrook representative or can be downloaded from www.norbrook.com. Norbrook also offers an iPhone App through which users can access essential product information including pharmaceutical presentation, uses, dosage and administration, withdrawal periods, contraindications & warnings and pharmaceutical precautions.
Ceva Animal Health has launched its 2013 ReprodAction desktop calendar, with a droll take on cycling cows.
The calendar is available free of charge to vet practices.
If you haven't received your calendar yet, contact Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
Ceva Animal Health has published Causes of scour in growing pigs: an overview, a technical review on pig scour.
The company says its aim is to provides vets with an easy-reference guide to the main causes and clinical signs of this common and potentially fatal condition.
At best, scour in growing pigs can cause significant weight loss and damage to the intestinal mucosa. At worst it will result in high mortality. Causes of scour in growing pigs: an overview summarises the causative agents of scour throughout the stages of growth, from sucking piglets through to finisher pigs.
Ceva adds that although it is difficult to be too prescriptive about assigning clinical signs to specific diseases because of variable immunity and the occurrence of mixed infections, the review provides useful guidelines to aid accurate diagnosis. Preventative management strategies are also discussed where applicable.
For further product information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
Expert speakers at Advances in Diagnostics, a meeting held in Brussels last month, have said that molecular technology will play a vital role in safeguarding the health and productivity of food animals in the future.
Dr Willie Loeffen, President of the European Association of Veterinary Laboratory Diagnosticians (EAVLD) said: "Technology is taking over. Laboratory diagnosis used to be 99% labour and 1% technology, nowadays the emphasis is the other way around. Technology is now an integral and indispensable part of veterinary laboratories."
Dr Loeffen used the investigation of PRRSV infection in pigs and the more recent appearance of Schmallenberg virus in Europe to highlight how modern molecular techniques could help to characterise new disease threats rapidly.
"It took four years of laborious work for us to characterise the cause of PRRS, but thanks to sequencing technology Schmallenberg virus took just a few months.
"Technological developments mean that diagnosticians now do things that they could only dream about 10 or 20 years ago."
As well as providing a means of identifying new disease threats quickly, the meeting highlighted the increasing role of diagnostic tools as an integral part of maintaining animal health.
Dr Kirk Adams, Director of Product Management at Life Technologies, the meeting sponsor, said: "Diagnostics are no longer just a way of finding out what an animal died of - they have a multitude of uses on farm. They mean that we can take a more holistic and proactive approach to animal health; in contrast to the reactive, disease-driven approach of the past.
"As just one example, better diagnostics allow a more targeted approach to treatment, and the potential to reduce the use of broad-spectrum drugs - such as certain antibiotics - and thus comply with the wishes of consumers and legislators."
Dr Adams said that modern diagnostic tools also provided the means to improve vaccination programmes and biosecurity, and were essential for disease eradication schemes and for improving herd health status, for example by identifying persistently infected, asymptomatic animals.
They also enable veterinary surgeons to monitor herd health and build up an accurate and dynamic picture of health status and risk profile - and screen for emerging disease threats.
Dr Adams added: "Veterinarians now have access to a wider range of better diagnostics than ever before. Tests are now faster, more accurate and more precise than ever before.
"The next twenty years could see the biggest change in the way we manage production animals in over a hundred years."
The meeting was also addressed by Dr Kees van Maanen, from the Netherlands Animal health Service (GD), an expert in modern diagnostic technology and its application on both local and national levels. He called for greater international co-operation to protect European animals against threats from increasing global interaction. He said: "Pathogens and insects do not respect borders: trusting each other's results requires further harmonization and transparency for diagnostic procedures between laboratories and countries.
"Rapid and accurate diagnosis contributes to disease management, but does not stop epidemics. However, it has contributed significantly to gaining insight into the epidemiology of emerging diseases and formulating appropriate measures.
"The development of modern diagnostics has given us the potential to manage animal health and control infectious diseases in production animals far more effectively in the past - both on a local level and a national or regional level. Recent experience with unexpected disease outbreaks has shown that we can now characterise and track pathogens far more quickly and accurately than ever before.
"However, we need to make sure that we keep veterinarians and farmers informed about these developments, so they know how to apply them in practice in order to make the most of them.
"Diagnostics will continue to become a more integral part of animal health management in the next decade, we just need to make sure we can apply that knowledge in the best possible way."
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
The Veterinary Marketing Association has announced a Practice Marketing Award, with a prize of £500 worth of CPD, for which entries are now being sought.
The award, which is sponsored by Merial, is open to companion and farm animal practices that can demonstrate effective marketing to their clients during the course of 2012.
For more information, visit: www.vma.org.uk/awards, or email: secretary@vma.org.uk for entry details.
Novartis Animal Health has been found in breach of the National Office of Animal Health Code on promotion.
The complaint related to a promotion at the National Sheep Association's 'Scotsheep 2012' on 6 June 2012, where Novartis had used the strapline 'Zolvix - the World's most effective wormer'.
The NOAH Committee unanimously took the view that the phrase constituted an all-embracing claim and a superlative which could not be substantiated.
Accordingly, the Committee found the promotion in breach of Clause 5.2.
The full details of the NOAH Committee's rulings is published on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortl.
Ceva Animal Health has launched ReprodAction, a new series of webinars to help address the problems commonly faced in bovine reproduction management.
James Husband, RCVS Specialist in Cattle Health and Reproduction, kicked off the series at the beginning of November with a live webinar for XLVet members: Assessing Fertility Records.
His presentation, which is now accessible to all large animal vets at http//onsync.digitalsamba.comn/go/ceva/ReprodAction, explores the common pitfalls and provides practical pointers for good fertility management. He discusses the limiting factors of oestrus detection, use of the calving interval as an assessor of individual fertility performance, implications of the varied definitions of conception rates, use of milk recording organisation data and the usefulness of the 21 day in calf rate.
Each webinar in the series is presented by a leading expert and has a facility for live chat and question and answer sessions.
For further information and details of when the next ReprodAction webinar will be taking place, contact Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
The badger culls planned to take place in West Somerset and West Gloucestershire this year have been postponed until 2013.
The postponement came at the request of The National Farmers Union (NFU), following new survey results which revealed higher than anticipated badger numbers in the two pilot areas (4,300 in West Somerset and 3,600 in West Gloucestershire ).
The NFU informed Defra that in light of these new figures they could not be confident of removing the required minimum 70% of the badgers in the two pilot areas this autumn.
Defra agreed to postpone the pilot culls until summer 2013 to allow farmers to continue their preparations and have the best possible chance of carrying out the cull effectively.
Environment Secretary Owen Paterson said: "Despite a greatly increased effort over the last few days and weeks, the farmers delivering this policy have concluded that they cannot be confident that it will be possible to remove enough badgers based on these higher numbers and considering the lateness of the season. It would be wrong to go ahead if those on the ground cannot be confident of removing at least 70% of the populations. Today I have received a letter from the President of the NFU, on behalf of the companies coordinating the culls, explaining why they do not feel they can go ahead this year and requesting that they be postponed until next summer. In these circumstances, it is the right thing to do and, as the people who have to deliver this policy on the ground and work within the science, I respect their decision.
"The Government is determined to tackle bovine TB by all the means available to us. Now, in the next few months, we will ensure that the pilot culls can be implemented effectively, in the best possible conditions, with the right resources. Having looked at all the evidence over many years, I am utterly convinced that badger control is the right thing to do, and indeed the higher than expected badger numbers only serve to underline the need for urgent action. I remain fully committed to working with the farming industry to ensure that the pilot culls can be delivered effectively, safely and humanely next summer."
The Government and NFU say they will now continue to plan so that the pilots can go ahead in Summer 2013.
Norbrook Laboratories has launched a ready-to-use suspension version of its Cefenil antibiotic.
Cefenil RTU (ceftiofur) is a 50mg/ml suspension for injection, indicated for cattle and swine.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Cefenil RTU is a broad spectrum injectable antibiotic offering fast and effective treatment of bacterial respiratory disease, foot rot and acute post-partum metritis in cattle as well as bacterial respiratory disease in swine. It offers a zero milk withhold and a 5-day meat withhold which is the shortest on the market."
Norbrook's Cefenil Powder and Solution for Injection has been available for a number of years for the treatment of cattle and swine. It has recently been indicated for the treatment of BRD in horses in the UK. Cefenil RTU will offer vets an additional choice in the treatment of BRD.
Dr McInerney added: "Cefenil is a tried and tested antibiotic which vets have been using for a number of years. We are delighted to extend the Cefenil range with a RTU suspension for cattle and pigs and adding an indication for horses to our Cefenil Powder and Solution for Injection. It gives vets a wider choice for the treatment of BRD with a product with which they are already familiar."
For further product information, visit www.norbrook.com.
The BVA has welcomed the decision to prohibit the advertising of antimicrobials directly to animal keepers from 2013 in a bid to reduce antimicrobial resistance.
The Veterinary Medicines Directorate (VMD) announced that the Veterinary Medicines Regulations will be revised next year. The change has come as a result of the European Commission's view that the UK did not correctly transpose the European Directive 2001/82/EC which prohibits the advertising of certain veterinary medicinal products to the 'general public'.
When the VMD consulted on proposals to restrict the advertising of antimicrobials to farmers in 2010 the BVA supported the measure as a sensible approach to the responsible use of antimicrobials.
In a letter to stakeholders the VMD explained that: "A number of interested parties from veterinary medicine hold the view that the advertising of antibiotics to keepers of animals leads to undue pressure to prescribe newer antibiotics, which can often be important in human medicine and are associated with the development of multiple resistances."
Peter Jones, President of the BVA, said: "The BVA has consistently argued for the restriction of advertising of antimicrobials to animal keepers and we believe this is the right decision.
"New antimicrobials are heavily advertised by pharmaceutical companies and there can be undue pressure put on veterinary surgeons by clients who want to try new products that promise good results, but which may not be appropriate from the point of view of responsible use.
"Antimicrobial resistance is a very serious issue for both animal and human health and we are pleased that the European Commission and the VMD have taken the view that the Regulations need to be revised.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets will continue to work with their farm clients to ensure antimicrobials are used prudently and responsibly."
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The Royal College of Veterinary Surgeons (RCVS) has clarified the legal position regarding the disbudding of goats, following recent media reports concerning undercover filming on UK goat farms.
The carrying out of any activity which amounts to veterinary surgery is restricted to veterinary surgeons unless there is a suitable exemption that allows other people to do it. The removal of the horn-bud of goats (disbudding) is considered veterinary surgery under the provisions of the Veterinary Surgeons Act 1966 (the Act).
Schedule 3 of the Act provides certain exemptions to the restriction on carrying out veterinary surgery, such as those allowing veterinary nurses and student veterinary nurses to undertake any medical treatment or any minor surgery (not involving entry into a body cavity) in certain circumstances. However, Schedule 3 specifically provides that these exemptions do not allow non-veterinary surgeons to undertake the disbudding of goats, except the trimming of the insensitive tip of an in-growing horn which, if left untreated, could cause pain or distress.
There are no other Exemption Orders covering the disbudding of goats and therefore this procedure may only be undertaken by veterinary surgeons.
The Mutilations (Permitted Procedures) (England) Regulations 2007, the Mutilations (Permitted Procedures) (Wales) Regulations 2007 and the Prohibited Procedures on Protected Animals (Exemptions) (Scotland) Regulations 2007 all include disbudding of goats as a procedure which can be carried out for non-therapeutic reasons. However, this secondary legislation is subject to the restrictions in the Veterinary Surgeons Act 1966 and therefore disbudding of goats is restricted to veterinary surgeons.The Welfare of Animals (Permitted Procedures By Lay Persons) Regulations (Northern Ireland) 2012 currently include disbudding of goats as a procedure which may be carried out by non-veterinary surgeons. However, the Veterinary Surgeons Act 1966 applies to Northern Ireland and the Regulations are scheduled to be amended later in 2012. This will make it clear that only veterinary surgeons may disbud goats in the UK.
The secondary legislation in the UK does not explicitly require anaesthetic to be administered when disbudding goats. However, disbudding should be carried out by veterinary surgeons in accordance with good practice and in such a way as to minimise pain and suffering caused to the animal, which should include use of an anaesthetic.
In summary, only a veterinary surgeon may undertake the disbudding of goats and due to the nature of the procedure, veterinary surgeons disbudding goats should administer anaesthetic.
Bulk milk surveillance for stomach worm exposure in dairy cows has found high levels in 68% of herds, with "probable sub-clinical effects on health and production", according to Pfizer Animal Health.
Between September 2011 and March this year, 449 milk samples submitted by dairy vets and SQP animal health advisers were analysed independently for Pfizer VPS.
Pfizer VPS vet Andrew Montgomery says that stomach worm (Ostertagia ostertagi) is the species identified most often in dairy cows1,2. and known to suppress appetite3: "Numerous trials have found a yield response to worming treatment, typically in the region of 1kg/cow/day."4
"At 25p/litre, this would be worth £76/cow over a 305-day lactation, or about £16,500/year in a typical 200-cow herd. Some trials have also identified improvements in reproductive performance although this remains to be proven absolutely."4
When test results indicate that worming is justified, Andrew recommends a moxidectin pour on treatment in the late dry period to maximise the gain over the highest yielding, early part of lactation.
The bulk milk surveillance programme is ongoing, and free Pfizer test kits are available from participating VPS animal medicine suppliers and veterinary practices.